Antibody-drug conjugates: beyond current approvals and potential future strategies
The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits of high specific targeting of oncogenic cell surface antigens with the additional cell kill from high...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2022-04-01
|
| Series: | Exploration of Targeted Anti-tumor Therapy |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/etat/Article/100282 |
| _version_ | 1811303667835338752 |
|---|---|
| author | Siddharth Menon Sagun Parakh Andrew M. Scott Hui K. Gan |
| author_facet | Siddharth Menon Sagun Parakh Andrew M. Scott Hui K. Gan |
| author_sort | Siddharth Menon |
| collection | DOAJ |
| description | The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits of high specific targeting of oncogenic cell surface antigens with the additional cell kill from high potency cytotoxic payloads, thus achieving wider therapeutic windows. This review will summarise the clinical activity of ADCs in tumour types not covered elsewhere in this issue, such as gastrointestinal (GI) and genitourinary (GU) cancers and glioblastoma (GBM). In addition to the ongoing clinical testing of existing ADCs, there is substantial preclinical and early phase testing of newer ADCs or ADC incorporating strategies. This review will provide selected insights into such future development, focusing on the development of novel ADCs against new antigen targets in the tumour microenvironment (TME) and combination of ADCs with immuno-oncology (IO) agents. |
| first_indexed | 2024-04-13T07:52:13Z |
| format | Article |
| id | doaj.art-3d8ef975652545ae9c093e8ae0cb2d09 |
| institution | Directory Open Access Journal |
| issn | 2692-3114 |
| language | English |
| last_indexed | 2024-04-13T07:52:13Z |
| publishDate | 2022-04-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Targeted Anti-tumor Therapy |
| spelling | doaj.art-3d8ef975652545ae9c093e8ae0cb2d092022-12-22T02:55:30ZengOpen Exploration Publishing Inc.Exploration of Targeted Anti-tumor Therapy2692-31142022-04-013225227710.37349/etat.2022.00082Antibody-drug conjugates: beyond current approvals and potential future strategiesSiddharth Menon0https://orcid.org/0000-0003-3863-6445Sagun Parakh1https://orcid.org/0000-0003-3891-2489Andrew M. Scott2https://orcid.org/0000-0002-6656-295XHui K. Gan3https://orcid.org/0000-0001-7319-8546Olivia Newton-John Cancer Centre at Austin Health, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg Victoria 3084, Australia; College of Science, Health and Engineering, La Trobe University, Melbourne Victoria 3086, AustraliaOlivia Newton-John Cancer Centre at Austin Health, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg Victoria 3084, Australia; College of Science, Health and Engineering, La Trobe University, Melbourne Victoria 3086, AustraliaOlivia Newton-John Cancer Centre at Austin Health, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg Victoria 3084, Australia; College of Science, Health and Engineering, La Trobe University, Melbourne Victoria 3086, AustraliaOlivia Newton-John Cancer Centre at Austin Health, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg Victoria 3084, Australia; College of Science, Health and Engineering, La Trobe University, Melbourne Victoria 3086, AustraliaThe recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits of high specific targeting of oncogenic cell surface antigens with the additional cell kill from high potency cytotoxic payloads, thus achieving wider therapeutic windows. This review will summarise the clinical activity of ADCs in tumour types not covered elsewhere in this issue, such as gastrointestinal (GI) and genitourinary (GU) cancers and glioblastoma (GBM). In addition to the ongoing clinical testing of existing ADCs, there is substantial preclinical and early phase testing of newer ADCs or ADC incorporating strategies. This review will provide selected insights into such future development, focusing on the development of novel ADCs against new antigen targets in the tumour microenvironment (TME) and combination of ADCs with immuno-oncology (IO) agents.https://www.explorationpub.com/Journals/etat/Article/100282antibody-drug conjugatesimmunotherapytumour microenvironment |
| spellingShingle | Siddharth Menon Sagun Parakh Andrew M. Scott Hui K. Gan Antibody-drug conjugates: beyond current approvals and potential future strategies Exploration of Targeted Anti-tumor Therapy antibody-drug conjugates immunotherapy tumour microenvironment |
| title | Antibody-drug conjugates: beyond current approvals and potential future strategies |
| title_full | Antibody-drug conjugates: beyond current approvals and potential future strategies |
| title_fullStr | Antibody-drug conjugates: beyond current approvals and potential future strategies |
| title_full_unstemmed | Antibody-drug conjugates: beyond current approvals and potential future strategies |
| title_short | Antibody-drug conjugates: beyond current approvals and potential future strategies |
| title_sort | antibody drug conjugates beyond current approvals and potential future strategies |
| topic | antibody-drug conjugates immunotherapy tumour microenvironment |
| url | https://www.explorationpub.com/Journals/etat/Article/100282 |
| work_keys_str_mv | AT siddharthmenon antibodydrugconjugatesbeyondcurrentapprovalsandpotentialfuturestrategies AT sagunparakh antibodydrugconjugatesbeyondcurrentapprovalsandpotentialfuturestrategies AT andrewmscott antibodydrugconjugatesbeyondcurrentapprovalsandpotentialfuturestrategies AT huikgan antibodydrugconjugatesbeyondcurrentapprovalsandpotentialfuturestrategies |